{"entity":{"id":"nct06792253","kind":"trial","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","aka":[],"tldr":"A phase 3 trial testing Ifupinostat in diffuse large B-cell lymphoma, now recruiting.","summary":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT06792253, led by BeBetter Med, and recruiting on the registry. Official title: Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Planned enrolment is 416 participants (estimated). The study started in 2025-01-06 and primary completion is expected in 2028-12-31. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06792253","url":"https://clinicaltrials.gov/study/NCT06792253"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["ifupinostat"],"companies":["bebetter-med"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06792253","phase":"3","setting":"Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","sponsor":"BeBetter Med","started":"2025-01-06","startedType":"actual","enrolled":416,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06792253/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"ifupinostat","kind":"drug","name":"Ifupinostat","route":"/drugs/ifupinostat/"}],"company":[{"id":"bebetter-med","kind":"company","name":"BeBetter Med","route":"/companies/bebetter-med/"}]}}